Medications for Colorectal Carcinoma

6 results

  • braftovi - encorafenib capsule

    (Encorafenib)
    Array Biopharma Inc.
    Braftovi treats unresectable or metastatic melanoma (BRAF V600E/V600K), metastatic colorectal cancer (BRAF V600E), and metastatic non-small cell lung cancer (BRAF V600E) in adults. Used in combination with binimetinib or cetuximab. Requires FDA-authorized BRAF mutation testing.
    Medication Details
    Drug Interactions

  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    KEYTRUDA is a PD-1 blocking antibody that treats multiple cancers—including melanoma, lung, head and neck, bladder, colorectal, gastric, cervical, breast, and renal cancers—as well as MSI-H/dMMR and TMB-H solid tumors, used across neoadjuvant, adjuvant, and metastatic settings.
    Medication Details
    Drug Interactions

  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
    Medication Details
    Drug Interactions

  • vectibix - panitumumab solution

    (Panitumumab)
    Amgen, Inc
    Vectibix (panitumumab) is an EGFR antagonist for adult metastatic colorectal cancer (mCRC). Treats wild-type RAS mCRC with FOLFOX as first-line or as monotherapy after prior chemo. Also treats KRAS G12C-mutated mCRC in combination with sotorasib after prior fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy.
    Medication Details
    Drug Interactions

  • yervoy - ipilimumab injection

    (Ipilimumab)
    E.R. Squibb & Sons, L.L.C.
    Yervoy treats multiple advanced cancers in adults and pediatric patients (12+), including melanoma, renal cell carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma—primarily in combination with nivolumab.
    Medication Details
    Drug Interactions